28 October 2025 in The Journal of Pharmacology and Experimental Therapeutics
Low-dose aspirin irreversibly acetylates cyclooxygenase (COX)-1 in anucleate platelets and progenitor megakaryocytes, permanently suppressing thromboxane (TX)A2-dependent platelet activation. Although aspirin pharmacodynamics is well characterized in platelets, the kinetics of COX inhibition and recovery in human megakaryocytes remains poorly defined, due to ethical issues associated with invasive, bone-marrow trephine sampling, and low megakaryocyte yield. We studied aspirin pharmacodynamics in human megakaryocytic cell lines as a reliable and feasible surrogate model. We characterized COX-1 and COX-2 expression and activity in MEG-01 and CHRF-288-11 megakaryocytic cell lines, treated with a range of aspirin concentrations and exposure duration. COX activity was quantified by the production of TXB2 from exogenous arachidonic acid. A single 10-μM aspirin exposure suppressed TXB2 by 90 ± 2% (MEG-01) and 85 ± 4% (CHRF-288-11), with full recovery within 48-72 hours. Both COX-isozymes were detected by western blot and immunohistochemistry; however, selective COX-1 inhibition by SC-560 reduced TXB2 by >75%, whereas COX-2 inhibition by NS-398 had minimal effect. Repeated aspirin exposure every 24 hours produced concentration- and time-dependent TXB2 suppression, achieving 89 ± 2% inhibition by day 2 at 1 μM and 73 ± 3% by day 4 at 0.1 μM. TXB2 biosynthesis recovered by 86 ± 2% and 99 ± 10% at days 2 and 3, respectively. These findings identify COX-1 as the principal source of TXA2 in megakaryocytes and demonstrate that aspirin inhibits megakaryocyte COX-1 time- and dose-dependently, with delayed recovery likely reflecting de novo synthesis of COX-1 protein, thereby providing mechanistic insight into the sustained antiplatelet effect of low-dose aspirin in humans. SIGNIFICANCE STATEMENT: In human megakaryocyte cell lines, once-daily aspirin treatment at low-concentration range time-dependently inhibits COX-1 with delayed recovery after aspirin withdrawal. This closely mimics the kinetics of platelets, supporting the translational utility of the megakaryocyte-based surrogate model.
27 July 2026 in Skin Health and Disease
Background: Activated platelets have been shown to promote tumorigenesis of several solid, largely gastrointestinal, tumours through the biosynthesis of cyclooxygenase-1-dependent thromboxane A2 (TXA2). The biosynthesis of the proinflammatory prostaglandin E2 (PGE2) has also been implicated in the progression of those solid tumours. Preclinical data suggest that platelet activation and PGE2 may contribute to melanoma progression, but clinical evidence is limited. Objectives: To investigate whether melanoma is associated with increased in vivo platelet activation and PGE2 biosynthesis, as assessed by urinary 11-dehydro-thromboxane B2 (11-dehydro-TXB2) and PGE2 metabolite (PGEM) levels, respectively, as compared with basal cell carcinoma (BCC) and healthy control samples; we also explored their potential relevance as biomarkers of melanoma progression. Methods: We measured urinary 11-dehydro-TXB2, a major TXA2 metabolite and a biomarker of in vivo platelet activation, as well as PGEM, in patients with melanoma and in patients with BCC, using age- and sex-matched healthy participants as controls. Thirty patients with stage 1–3 melanoma [mean (SD) age 57 (15) years; 21 men] and 24 patients with BCC [mean (SD) age 60 (12) years; 11 men] voluntarily participated in the study; 38 age- and sex-matched healthy individuals [mean (SD) age 56 (17) years; 26 men] from previously published studies by our group were included as controls. Results: Urinary 11-dehydro-TXB2 was higher in patients with melanoma [median 1284 pg mg–1 creatinine; interquartile range (IQR) 892–1784] vs. those with BCC (median 583 pg mg–1 creatinine; IQR 393–721) and healthy control participants (median 669 pg mg–1 creatinine; IQR 411–1184) (P < 0.001). Urinary 11-dehydro-TXB2 was comparable between patients with BCC and healthy control participants. We also studied six patients with stage 4 melanoma who showed the highest urinary 11-dehydro-TXB2 levels [1898.0 (IQR 1769.3–2622.1); P = 0.005 vs. all other groups]. PGEM levels did not differ among groups. Conclusions: Melanoma, unlike BCC, is associated with increased biosynthesis of biomarkers of activated platelets. Urinary 11-dehydro-TXB2 may be tested as a prognostic biomarker for melanoma progression. Moreover, whether inhibition of platelet activation may be an adjuvant chemopreventive strategy warrants further investigation.